New Study Shows Cardio Diagnostics (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually
–News Direct– By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has announced the publication of results from a budget impact modeling study for one of its leading clinical products. PrecisionCHD is an integrated genetic-epigenetic test for the detection…